A Phase 1 interventional study of Bev-ICG and NIR-II fluorescence endoscopy platform in Gastrointestinal Carcinoma, Dysplasia and Gastrointestinal Polyp, sponsored by Institute of Automation, Chinese Academy of Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by Institute of Automation, Chinese Academy of Sciences · Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Polyps with a site in China — 13 open to participants now, 15 under way, none of them phase 3. Polyps · China.
Among the 51 studies in Polyps with a site in China, this one is the 32nd largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 1, reaches primary completion later than 3 of the 14 other live ones, and was the 36th registered.
312 studies on the registry are indexed under Polyps; 59 are open to participants now.
Browse Polyps studies →13 of the 51 studies in Polyps with a site in China are open now. Recruiting first, the newest first:
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75 · Healthy volunteers
The First Hospital of Jilin University · Sites in China
Changhai Hospital · Sites in China
Ages 18–85
Renmin Hospital of Wuhan University · Sites in China
Ages 50+
Peking Union Medical College Hospital · Sites in China
Ages 40–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 34 Polyps studies recruiting now, 25 (74%) set no upper age limit and 6 (18%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 150 across 204 interventional studies indexed under Polyps.
Median enrollment 351 across the 32 interventional studies, 300 across the 19 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 51 have an industry lead sponsor. The 10 most frequent:
Institute of Automation, Chinese Academy of Sciences is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Institute of Automation, Chinese Academy of Sciences has 1 study filed under Polyps — fewer than ten, so there is no comparison to draw.
5 of the studies in Polyps with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06924489Xijing Hospital of Digestive DiseasesAdvanced Adenoma Detection With 3D Imaging Device During Colonoscopy | 2026-12-01 |
| NCT07708415Gansu Provincial HospitalThe Correlation of Postoperative Polyp Recurrence and Colorectal Cancer | 2026-12-31 |
| NCT06937047Shandong UniversityEfficacy and Safety of Cold Versus Hot Snare Polypectomy for Removal of 4-10 mm Pedunculated Colorectal Polyps | 2027-01-01 |
| NCT06996522Fudan UniversityUEMR Versus HSP in the Treatment of Pedunculated Colorectal Polyps Less Than 10mm in Size | 2027-07-31 |
| NCT07793110Renmin Hospital of Wuhan UniversityEarly Diagnosis Model of Colorectal Adenoma Using Laboratory Examinations | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 51 studies in Polyps with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the investigators are studying new ways to look for abnormal tissues of the gastrointestinal tract during an endoscopy. We are using a VEGF-A targeting fluorescent probe and a NIR-II fluorescent endoscope to help detect abnormal tissues that are hard to see by the naked eye.
The main purposes of this study include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients will receive a topical administration of probe (Bev-ICG) during the endoscopy. Then fluorescence imaging will be performed to guide the detection.
Drug: Bev-ICG · Device: NIR-II fluorescence endoscopy platform
Probe targeting VEGF-A that is topically administrated during the endoscopy
An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
Validation of NIR-II endoscope and probe targeting VEGF-A
Demonstrate the feasibility of using the NIR-II endoscope and VEGF-A targeting fluorescent probe to image abnormal tissues of the gastrointestinal tract.
Time frame: During endoscopy
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for May 2025, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Automation, Chinese Academy of Sciences